Myeloma News and Research

RSS

New insights into cancer genome may lead to designer drugs for myeloma

Patients with myeloma could benefit from ‘designer’ drugs in the future after new genome-mapping technology has allowed scientists to identify a full genetic blueprint of the mutations which drive the bone marrow cancer.

23 Mar 2011

$Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty$

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

Medtronic of Canada Ltd. today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients.

23 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Experts to present latest information on multiple myeloma at Patient Symposium

The Multiple Myeloma Research Foundation and the John Theurer Cancer Center at Hackensack University Medical Center, member of the Multiple Myeloma Research Consortium, will host the MMRF Clinical Insights in Multiple Myeloma Patient Symposium on Saturday, April 2 in Short Hills, NJ from 9:00am-3:30pm.

18 Mar 2011

CTI, Chroma enter agreement to co-develop and license tosedostat

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced today that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma's drug candidate tosedostat in North, Central and South America.

14 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

FDA holds Senesco's SNS01-T clinical study due to delay of supplier's DMF updation

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration has informed the Company that its planned study in multiple myeloma is on hold until the Drug Master File of one of its suppliers is updated.

11 Mar 2011

Yakult Honsha, AEZS sign agreement to develop, commercialize and license perifosine

Aeterna Zentaris Inc. and Yakult Honsha Co., Ltd. today announced the signing of an exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for Japan.

9 Mar 2011

Mintz Levin's Health Law Practice to sponsor WBL's 10th Annual Summit

The Health Law Practice of Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. is a sponsor of the Women Business Leaders of the U.S. Health Care Industry Foundation and WBL's 10th Annual Summit.

5 Mar 2011

BioSante vaccine increases median survival of resected pancreatic cancer patients

BioSante Pharmaceuticals, Inc. today announced publication of results from a Phase II clinical study that show BioSante's Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent.

4 Mar 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

FDA clears ArthroCare's Parallax Contour-enhanced Vertebral Augmentation Device

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the U.S. Food and Drug Administration to market its second-generation Parallax Contour -enhanced Vertebral Augmentation Device specifically for void creation in a vertebral body followed by injection of bone cement.

22 Feb 2011

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.

21 Feb 2011

Medtronic: Kyphon Balloon Kyphoplasty provides better back pain relief in cancer patients

Medtronic Inc., today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients. The study found that Kyphon Balloon Kyphoplasty provided cancer patients better back-specific function, more rapid back pain relief and improved quality of life compared with non-surgical care one month after treatment.

17 Feb 2011

Scientists develop novel treatment strategy for multiple myeloma

Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.

11 Feb 2011

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.

10 Feb 2011

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies show that bafetinib may be useful in preventing bone loss in cancer patients who are at high risk for this event.

8 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011